OICR-9429

• CAT Number: I002343
• CAS Number: 1801787-56-3
• Molecular Formula: C₂₉H₃₂F₃N₅O₃
• Molecular Weight: 555.59
• Purity: ≥95%
• Synonyms: N-(4-(4-methylpiperazin-1-yl)-3/’-(morpholinomethyl)-[1,1/’-biphenyl]-3-yl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide
• Target: Apoptosis
• Solubility: DMSO ≥ 32 mg/mL
• Storage: Store at -20°C
• IUPAC Name: N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1H-pyridine-3-carboxamide
• InChI: InChI=1S/C29H32F3N5O3/c1-35-7-9-37(10-8-35)26-6-5-22(21-4-2-3-20(15-21)19-36-11-13-40-14-12-36)16-25(26)34-28(39)23-18-33-27(38)17-24(23)29(30,31)32/h2-6,15-18H,7-14,19H2,1H3,(H,33,38)(H,34,39)
• InChIKey: DJOVLOYCGXNVPI-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)C2=C(C=C(C=C2)C3=CC=CC(=C3)CN4CCOCC4)NC(=O)C5=CNC(=O)C=C5C(F)(F)F

OICR-9429（Cat No.:I002343）is a selective inhibitor of the enzyme bromodomain and extraterminal domain (BET) proteins, particularly BRD4, which are involved in regulating gene expression associated with cancer cell proliferation and survival. By inhibiting BET proteins, OICR-9429 disrupts oncogenic transcriptional programs, leading to reduced tumor growth and increased apoptosis in cancer cells. This compound has shown promise in preclinical studies, especially in hematologic malignancies and solid tumors, highlighting its potential as a therapeutic agent. OICR-9429’s targeted mechanism provides valuable insights into the role of BET proteins in cancer and offers avenues for developing targeted therapies.

Reference

[1]. Grebien F et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
Nat Chem Biol. 2015 Aug;11(8):571-8.

[2]. Getlik M et al. Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1). J Med Chem. 2016 Mar 24;59(6):2478-96.